About Inositol-trisphosphate 3-kinase A
Inositol-trisphosphate 3-kinase A (ITPKA) is a protein
from Homo sapiens identified by UniProt accession
P23677, 461 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Inositol-trisphosphate 3-kinase A |
| UniProt accession | P23677 |
| Gene | ITPKA |
| Organism | Homo sapiens |
| Length | 461 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.34
- eosinophil percentage of leukocytes · score 0.29
- cystatin C measurement · score 0.23
- Eczematoid dermatitis · score 0.22
- asthma · score 0.21
- allergic rhinitis · score 0.20
- cutaneous melanoma · score 0.18
- neutrophil count · score 0.17
- childhood onset asthma · score 0.16
- allergic disease · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P23677-F1 | alphafold | PREDICTED | 71.48 | — |
Amino-acid sequence (461 residues)
MTLPGGPTGM ARPGGARPCS PGLERAPRRS VGELRLLFEA RCAAVAAAAA AGEPRARGAK RRGGQVPNGL PRAPPAPVIP QLTVTAEEPD VPPTSPGPPE RERDCLPAAG SSHLQQPRRL STSSVSSTGS SSLLEDSEDD LLSDSESRSR GNVQLEAGED VGQKNHWQKI RTMVNLPVIS PFKKRYAWVQ LAGHTGSFKA AGTSGLILKR CSEPERYCLA RLMADALRGC VPAFHGVVER DGESYLQLQD LLDGFDGPCV LDCKMGVRTY LEEELTKARE RPKLRKDMYK KMLAVDPEAP TEEEHAQRAV TKPRYMQWRE GISSSTTLGF RIEGIKKADG SCSTDFKTTR SREQVLRVFE EFVQGDEEVL RRYLNRLQQI RDTLEVSEFF RRHEVIGSSL LFVHDHCHRA GVWLIDFGKT TPLPDGQILD HRRPWEEGNR EDGYLLGLDN LIGILASLAE R
Explore Inositol-trisphosphate 3-kinase A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets